TABLE 1.
Vaccine | Immunization routea | Antibody titerb
|
|||||
---|---|---|---|---|---|---|---|
Serum IgG
|
Fecal IgA
|
Lung wash IgA
|
|||||
FLA | LT | FLA | LT | FLA | LT | ||
ICB5 | i.p. | 32,180 ± 2,574 | ND | ND | ND | ND | ND |
Oral | 50 ± 6 | <2 | <2 | <2 | ND | ND | |
Nasal | 16 ± 2 | <2 | ND | <2 | 82 ± 9 | ND | |
ICB5 plus LT | Oral | 51 ± 4 | 10,683 ± 961 | 3 ± 1 | 41 ± 4 | ND | ND |
Nasal | 10 ± 2 | 2 × 106 ± 1.6 × 104 | ND | ND | 104 ± 12 | 8,000 ± 796 |
Immunizations were carried out with three doses of 1010 CFU (p.o.) or 107 CFU (i.n. or i.p.) on days 0, 21, and 35. Serum, fecal, and lung wash samples were collected 1 week after the last immunization dose.
Titers were determined in ELISA plates treated with type d flagellin (FLA) or purified LTR192G (LT). Values are means of endpoint titers ± SEM of serum pools prepared from each mouse group. Data are based on two independent experiments. ND, not done.